Intrinsic value of BioCryst Pharmaceuticals - BCRX

Previous Close

$6.99

  Intrinsic Value

$0.19

stock screener

  Rating & Target

str. sell

-97%

Previous close

$6.99

 
Intrinsic value

$0.19

 
Up/down potential

-97%

 
Rating

str. sell

We calculate the intrinsic value of BCRX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.8

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  40
  62
  93
  135
  191
  262
  352
  462
  594
  751
  932
  1,140
  1,374
  1,634
  1,922
  2,235
  2,575
  2,940
  3,330
  3,743
  4,181
  4,641
  5,125
  5,631
  6,160
  6,711
  7,285
  7,882
  8,503
  9,148
Variable operating expenses, $m
  114
  177
  264
  384
  541
  744
  999
  1,312
  1,688
  2,132
  2,647
  3,236
  3,901
  4,641
  5,457
  6,348
  7,313
  8,349
  9,456
  10,631
  11,874
  13,182
  14,555
  15,992
  17,493
  19,059
  20,689
  22,385
  24,149
  25,982
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  114
  177
  264
  384
  541
  744
  999
  1,312
  1,688
  2,132
  2,647
  3,236
  3,901
  4,641
  5,457
  6,348
  7,313
  8,349
  9,456
  10,631
  11,874
  13,182
  14,555
  15,992
  17,493
  19,059
  20,689
  22,385
  24,149
  25,982
Operating income, $m
  -74
  -115
  -171
  -249
  -351
  -482
  -647
  -850
  -1,093
  -1,381
  -1,715
  -2,097
  -2,527
  -3,007
  -3,536
  -4,113
  -4,738
  -5,409
  -6,126
  -6,888
  -7,693
  -8,540
  -9,430
  -10,361
  -11,334
  -12,348
  -13,404
  -14,503
  -15,646
  -16,833
EBITDA, $m
  -73
  -113
  -169
  -245
  -345
  -475
  -637
  -837
  -1,077
  -1,360
  -1,689
  -2,065
  -2,489
  -2,961
  -3,482
  -4,050
  -4,665
  -5,326
  -6,032
  -6,782
  -7,575
  -8,409
  -9,285
  -10,202
  -11,160
  -12,159
  -13,199
  -14,281
  -15,406
  -16,575
Interest expense (income), $m
  0
  9
  14
  23
  34
  50
  71
  97
  131
  172
  222
  280
  348
  426
  513
  611
  718
  836
  963
  1,099
  1,245
  1,400
  1,564
  1,736
  1,917
  2,106
  2,304
  2,510
  2,725
  2,948
  3,181
Earnings before tax, $m
  -83
  -129
  -194
  -283
  -401
  -553
  -744
  -981
  -1,266
  -1,603
  -1,995
  -2,445
  -2,953
  -3,520
  -4,147
  -4,831
  -5,573
  -6,372
  -7,225
  -8,133
  -9,093
  -10,104
  -11,166
  -12,278
  -13,440
  -14,652
  -15,914
  -17,228
  -18,594
  -20,014
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -83
  -129
  -194
  -283
  -401
  -553
  -744
  -981
  -1,266
  -1,603
  -1,995
  -2,445
  -2,953
  -3,520
  -4,147
  -4,831
  -5,573
  -6,372
  -7,225
  -8,133
  -9,093
  -10,104
  -11,166
  -12,278
  -13,440
  -14,652
  -15,914
  -17,228
  -18,594
  -20,014

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  161
  249
  372
  540
  762
  1,048
  1,407
  1,847
  2,377
  3,002
  3,728
  4,558
  5,494
  6,537
  7,687
  8,941
  10,300
  11,759
  13,318
  14,973
  16,723
  18,566
  20,500
  22,524
  24,638
  26,843
  29,139
  31,528
  34,012
  36,594
Adjusted assets (=assets-cash), $m
  161
  249
  372
  540
  762
  1,048
  1,407
  1,847
  2,377
  3,002
  3,728
  4,558
  5,494
  6,537
  7,687
  8,941
  10,300
  11,759
  13,318
  14,973
  16,723
  18,566
  20,500
  22,524
  24,638
  26,843
  29,139
  31,528
  34,012
  36,594
Revenue / Adjusted assets
  0.248
  0.249
  0.250
  0.250
  0.251
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
  0.250
Average production assets, $m
  16
  24
  36
  53
  74
  102
  137
  180
  231
  292
  363
  443
  534
  636
  748
  870
  1,002
  1,144
  1,295
  1,456
  1,626
  1,806
  1,994
  2,190
  2,396
  2,610
  2,834
  3,066
  3,308
  3,559
Working capital, $m
  -51
  -79
  -119
  -172
  -243
  -334
  -449
  -589
  -758
  -958
  -1,189
  -1,454
  -1,753
  -2,085
  -2,452
  -2,852
  -3,286
  -3,751
  -4,248
  -4,777
  -5,335
  -5,923
  -6,539
  -7,185
  -7,860
  -8,563
  -9,295
  -10,057
  -10,850
  -11,673
Total debt, $m
  91
  143
  216
  315
  447
  616
  828
  1,089
  1,403
  1,773
  2,203
  2,694
  3,248
  3,865
  4,546
  5,289
  6,093
  6,957
  7,880
  8,860
  9,896
  10,986
  12,131
  13,330
  14,581
  15,887
  17,246
  18,660
  20,131
  21,659
Total liabilities, $m
  95
  147
  220
  320
  451
  620
  833
  1,094
  1,407
  1,777
  2,207
  2,699
  3,253
  3,870
  4,550
  5,293
  6,097
  6,961
  7,884
  8,864
  9,900
  10,991
  12,136
  13,334
  14,586
  15,891
  17,250
  18,665
  20,135
  21,663
Total equity, $m
  66
  102
  152
  220
  311
  428
  574
  754
  970
  1,225
  1,521
  1,860
  2,242
  2,667
  3,136
  3,648
  4,202
  4,798
  5,434
  6,109
  6,823
  7,575
  8,364
  9,190
  10,052
  10,952
  11,889
  12,863
  13,877
  14,930
Total liabilities and equity, $m
  161
  249
  372
  540
  762
  1,048
  1,407
  1,848
  2,377
  3,002
  3,728
  4,559
  5,495
  6,537
  7,686
  8,941
  10,299
  11,759
  13,318
  14,973
  16,723
  18,566
  20,500
  22,524
  24,638
  26,843
  29,139
  31,528
  34,012
  36,593
Debt-to-equity ratio
  1.380
  1.410
  1.420
  1.430
  1.440
  1.440
  1.440
  1.440
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
  1.450
Adjusted equity ratio
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408
  0.408

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -83
  -129
  -194
  -283
  -401
  -553
  -744
  -981
  -1,266
  -1,603
  -1,995
  -2,445
  -2,953
  -3,520
  -4,147
  -4,831
  -5,573
  -6,372
  -7,225
  -8,133
  -9,093
  -10,104
  -11,166
  -12,278
  -13,440
  -14,652
  -15,914
  -17,228
  -18,594
  -20,014
Depreciation, amort., depletion, $m
  1
  2
  3
  4
  5
  7
  10
  13
  17
  21
  26
  32
  39
  46
  54
  63
  73
  83
  94
  106
  118
  131
  144
  159
  174
  189
  205
  222
  240
  258
Funds from operations, $m
  -82
  -127
  -191
  -279
  -395
  -545
  -735
  -968
  -1,249
  -1,582
  -1,969
  -2,413
  -2,914
  -3,474
  -4,092
  -4,768
  -5,501
  -6,289
  -7,132
  -8,027
  -8,975
  -9,973
  -11,021
  -12,119
  -13,266
  -14,463
  -15,709
  -17,006
  -18,354
  -19,756
Change in working capital, $m
  -19
  -28
  -39
  -54
  -71
  -91
  -114
  -141
  -169
  -199
  -232
  -265
  -299
  -333
  -367
  -400
  -433
  -466
  -497
  -528
  -558
  -588
  -617
  -646
  -674
  -703
  -732
  -762
  -792
  -824
Cash from operations, $m
  -62
  -99
  -152
  -225
  -324
  -454
  -620
  -827
  -1,080
  -1,382
  -1,737
  -2,148
  -2,616
  -3,142
  -3,726
  -4,368
  -5,068
  -5,823
  -6,634
  -7,499
  -8,416
  -9,385
  -10,404
  -11,473
  -12,592
  -13,759
  -14,976
  -16,244
  -17,562
  -18,932
Maintenance CAPEX, $m
  -1
  -1
  -2
  -3
  -4
  -5
  -7
  -10
  -13
  -17
  -21
  -26
  -32
  -39
  -46
  -54
  -63
  -73
  -83
  -94
  -106
  -118
  -131
  -144
  -159
  -174
  -189
  -205
  -222
  -240
New CAPEX, $m
  -6
  -9
  -12
  -16
  -22
  -28
  -35
  -43
  -52
  -61
  -71
  -81
  -91
  -101
  -112
  -122
  -132
  -142
  -152
  -161
  -170
  -179
  -188
  -197
  -206
  -214
  -223
  -232
  -242
  -251
Cash from investing activities, $m
  -7
  -10
  -14
  -19
  -26
  -33
  -42
  -53
  -65
  -78
  -92
  -107
  -123
  -140
  -158
  -176
  -195
  -215
  -235
  -255
  -276
  -297
  -319
  -341
  -365
  -388
  -412
  -437
  -464
  -491
Free cash flow, $m
  -69
  -109
  -166
  -244
  -350
  -487
  -662
  -880
  -1,144
  -1,460
  -1,829
  -2,255
  -2,739
  -3,282
  -3,884
  -4,544
  -5,263
  -6,038
  -6,869
  -7,754
  -8,692
  -9,682
  -10,723
  -11,815
  -12,956
  -14,147
  -15,389
  -16,681
  -18,025
  -19,423
Issuance/(repayment) of debt, $m
  36
  52
  73
  99
  131
  169
  212
  261
  314
  370
  430
  491
  554
  617
  680
  743
  804
  864
  923
  980
  1,036
  1,091
  1,145
  1,198
  1,252
  1,305
  1,359
  1,414
  1,470
  1,528
Issuance/(repurchase) of shares, $m
  108
  165
  244
  351
  491
  669
  891
  1,160
  1,482
  1,858
  2,291
  2,783
  3,335
  3,946
  4,615
  5,343
  6,128
  6,967
  7,861
  8,808
  9,807
  10,856
  11,955
  13,104
  14,302
  15,551
  16,851
  18,202
  19,607
  21,067
Cash from financing (excl. dividends), $m  
  144
  217
  317
  450
  622
  838
  1,103
  1,421
  1,796
  2,228
  2,721
  3,274
  3,889
  4,563
  5,295
  6,086
  6,932
  7,831
  8,784
  9,788
  10,843
  11,947
  13,100
  14,302
  15,554
  16,856
  18,210
  19,616
  21,077
  22,595
Total cash flow (excl. dividends), $m
  75
  108
  152
  206
  273
  351
  441
  541
  651
  768
  892
  1,020
  1,150
  1,281
  1,412
  1,542
  1,669
  1,794
  1,915
  2,034
  2,150
  2,264
  2,376
  2,487
  2,598
  2,709
  2,821
  2,935
  3,052
  3,172
Retained Cash Flow (-), $m
  -108
  -165
  -244
  -351
  -491
  -669
  -891
  -1,160
  -1,482
  -1,858
  -2,291
  -2,783
  -3,335
  -3,946
  -4,615
  -5,343
  -6,128
  -6,967
  -7,861
  -8,808
  -9,807
  -10,856
  -11,955
  -13,104
  -14,302
  -15,551
  -16,851
  -18,202
  -19,607
  -21,067
Prev. year cash balance distribution, $m
  43
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  10
  -57
  -93
  -145
  -218
  -318
  -450
  -619
  -831
  -1,089
  -1,399
  -1,764
  -2,185
  -2,664
  -3,203
  -3,801
  -4,459
  -5,174
  -5,946
  -6,774
  -7,656
  -8,591
  -9,578
  -10,616
  -11,704
  -12,842
  -14,030
  -15,267
  -16,555
  -17,895
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  10
  -52
  -81
  -119
  -169
  -231
  -304
  -387
  -477
  -571
  -665
  -753
  -831
  -894
  -940
  -966
  -970
  -953
  -916
  -861
  -792
  -713
  -628
  -541
  -455
  -375
  -301
  -236
  -181
  -135
Current shareholders' claim on cash, %
  77.6
  60.9
  48.2
  38.5
  30.9
  25.0
  20.4
  16.7
  13.7
  11.3
  9.4
  7.8
  6.6
  5.5
  4.6
  3.9
  3.3
  2.8
  2.4
  2.0
  1.7
  1.5
  1.2
  1.1
  0.9
  0.8
  0.7
  0.6
  0.5
  0.4

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

FINANCIAL RATIOS  of  BioCryst Pharmaceuticals (BCRX)

Valuation Ratios
P/E Ratio -9.4
Price to Sales 19.8
Price to Book 257.9
Price to Tangible Book
Price to Cash Flow -9.7
Price to Free Cash Flow -8.9
Growth Rates
Sales Growth Rate -45.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 2
Current Ratio 0
LT Debt to Equity 1300%
Total Debt to Equity 2700%
Interest Coverage 0
Management Effectiveness
Return On Assets -51.9%
Ret/ On Assets - 3 Yr. Avg. -44.5%
Return On Total Capital -82.1%
Ret/ On T. Cap. - 3 Yr. Avg. -65.2%
Return On Equity -220%
Return On Equity - 3 Yr. Avg. -136.5%
Asset Turnover 0.2
Profitability Ratios
Gross Margin 92.3%
Gross Margin - 3 Yr. Avg. 96.7%
EBITDA Margin -211.5%
EBITDA Margin - 3 Yr. Avg. -207.5%
Operating Margin -188.5%
Oper. Margin - 3 Yr. Avg. -197.7%
Pre-Tax Margin -211.5%
Pre-Tax Margin - 3 Yr. Avg. -207.5%
Net Profit Margin -211.5%
Net Profit Margin - 3 Yr. Avg. -207.5%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

BCRX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the BCRX stock intrinsic value calculation we used $25.186 million for the last fiscal year's total revenue generated by BioCryst Pharmaceuticals. The default revenue input number comes from 0001 income statement of BioCryst Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our BCRX stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for BCRX is calculated based on our internal credit rating of BioCryst Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of BioCryst Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of BCRX stock the variable cost ratio is equal to 284%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for BCRX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 15.8% for BioCryst Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for BioCryst Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the BCRX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for BCRX are equal to 38.9%.

Life of production assets of 13.8 years is the average useful life of capital assets used in BioCryst Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for BCRX is equal to -127.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $83.767 million for BioCryst Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 109.382 million for BioCryst Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of BioCryst Pharmaceuticals at the current share price and the inputted number of shares is $0.8 billion.

RELATED COMPANIES Price Int.Val. Rating
GILD Gilead Science 70.55 155.76  str.buy
SRPT Sarepta Therap 111.99 2.96  str.sell
VICL Vical 1.22 0.72  sell

COMPANY NEWS

▶ BioCryst to Present at Upcoming Investor Conferences   [Nov-08-18 07:00AM  GlobeNewswire]
▶ BioCryst: 3Q Earnings Snapshot   [07:27AM  Associated Press]
▶ Grifols (GRFS) Surges: Stock Moves 5.4% Higher   [Oct-12-18 09:17AM  Zacks]
▶ Here's Why BioCryst Pharmaceuticals Rose 21.3% in August   [Sep-10-18 12:36PM  Motley Fool]
▶ RTP pharma scores $35M contract to supply CDC   [Sep-06-18 01:45PM  American City Business Journals]
▶ Inside The List: Highest-Paid Public Company CEOs   [Sep-04-18 02:38PM  American City Business Journals]
▶ BioCryst banks gross proceeds of $57.5M from offering   [Aug-07-18 03:38PM  American City Business Journals]
▶ BioCryst: 2Q Earnings Snapshot   [06:05AM  Associated Press]
▶ BioCryst gets FDA nod on key drug   [02:18PM  American City Business Journals]
▶ After Idera deal called off, BioCryst looks to raise $50M   [Aug-02-18 04:13PM  American City Business Journals]
▶ Future of Idera's Cambridge office uncertain after failed merger   [11:56AM  American City Business Journals]
▶ No deal: BioCryst shareholders thwart merger with Idera   [Jul-10-18 06:00PM  American City Business Journals]
▶ BioCryst: 1Q Earnings Snapshot   [09:37AM  Associated Press]
▶ BioCryst lands European approval for flu treatment   [May-02-18 08:24AM  American City Business Journals]
▶ Vote on proposed merger of biopharm firms pushed back   [Apr-10-18 02:51PM  American City Business Journals]
▶ Why another BioCryst shareholder plans to vote against Idera merger   [Apr-03-18 02:38PM  American City Business Journals]
▶ BioCryst reports 4Q loss   [09:31AM  Associated Press]
▶ BioCryst, Idera outline specifics on merger value   [Feb-26-18 08:45AM  American City Business Journals]
▶ Durham's BioCryst merging with Idera, moving some ops out of state   [02:20PM  American City Business Journals]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.